China Medical System Holdings (HKG:867) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥7.47b (down 6.8% from FY 2023).
- Net income: CN¥1.62b (down 33% from FY 2023).
- Profit margin: 22% (down from 30% in FY 2023). The decrease in margin was primarily driven by lower revenue.
- EPS: CN¥0.67 (down from CN¥0.98 in FY 2023).
867 Products In Clinical Trials
- Phase I: 2.
- Phase II: 4.
- Phase III: 8.
867 Post-Clinical Trial Products
- Pre-registration: 8.
- Approved (during full year): 2.
All figures shown in the chart above are for the trailing 12 month (TTM) period
China Medical System Holdings Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) also missed analyst estimates by 7.9%.
In the last 12 months, the only revenue segment was Marketing, Promotion, Sales and Manufacturing of Pharmaceutical Products contributing CN¥7.47b. The largest operating expense was Sales & Marketing costs, amounting to CN¥2.66b (70% of total expenses). Explore how 867's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Hong Kong.
Performance of the Hong Kong Pharmaceuticals industry.
The company's shares are up 11% from a week ago.
Risk Analysis
It is worth noting though that we have found 1 warning sign for China Medical System Holdings that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.